Elicio Therapeutics (ELTX) Cash from Investing Activities (2020 - 2025)
Elicio Therapeutics' (ELTX) quarterly Cash from Investing Activities came in at -$16000.0 in Q4 2025, up 64.44% YoY from -$9729.7 in Q4 2024, and up 64.44% on a QoQ basis from -$45000.0 in Q4 2024.
Elicio Therapeutics (ELTX) Cash from Investing Activities (2020 - 2025) Analysis & Trends
Elicio Therapeutics (ELTX) has 6 years of Cash from Investing Activities data on file, last reported at -$16000.0 in Q4 2025.
- Quarterly Cash from Investing Activities rose 64.44% year-over-year to -$16000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$16000.0 (up 80.95% YoY) and the FY2025 annual result came in at -$16000.0, up 80.95% from the prior year.
- Cash from Investing Activities improved to -$16000.0 in Q4 2025, from -$45000.0 in the prior quarter.
- In the past five years, Cash from Investing Activities ranged from a high of $30000.0 in Q2 2023 to a low of -$559000.0 in Q2 2022.
- A 5-year average of -$89846.2 and a median of -$42000.0 in 2024 frame the typical range for Cash from Investing Activities.
- Annual changes were most pronounced in 2021 — Cash from Investing Activities plunged 6000.0% — and 2024, when it soared 117.65%.
- Tracing ELTX's Cash from Investing Activities over 5 years: stood at -$36000.0 in 2021, then plunged by 163.89% to -$95000.0 in 2022, then surged by 52.63% to -$45000.0 in 2023, then changed by 0.0% to -$45000.0 in 2024, then surged by 64.44% to -$16000.0 in 2025.
- The last three Cash from Investing Activities figures came in at -$16000.0 (Q4 2025), -$45000.0 (Q4 2024), and -$42000.0 (Q2 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -45.80 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -92.70 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 329.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | -49.35 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -363.46 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -3.17 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 24.51 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -229.72 Mn |
| 10 | Elicio Therapeutics | 58.41 Mn | 34.91 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -16,000.00 |
| Dec 31, 2025 | -16,000.00 |
| Dec 31, 2024 | -45,000.00 |
| Dec 31, 2024 | -45,000.00 |
| Jun 30, 2024 | -42,000.00 |
| Jun 30, 2024 | -42,000.00 |
| Mar 31, 2024 | 3,000.00 |
| Mar 31, 2024 | 3,000.00 |
| Sep 30, 2023 | -45,000.00 |
| Sep 30, 2023 | -45,000.00 |
| Jun 30, 2023 | 30,000.00 |
| Jun 30, 2023 | 30,000.00 |
| Mar 31, 2023 | -17,000.00 |
| Mar 31, 2023 | -17,000.00 |
| Dec 31, 2022 | -95,000.00 |
| Dec 31, 2022 | -95,000.00 |
| Jun 30, 2022 | -559,000.00 |
| Jun 30, 2022 | -559,000.00 |
| Dec 31, 2021 | -36,000.00 |
| Dec 31, 2021 | -36,000.00 |